Pulse is a free monthly letter on innovation in diabetes care, sent to a community of about 14,000 clinicians, researchers, and industry readers.
Once a month, three to five things from across the diabetes innovation landscape — from limb preservation to endocrinology, from vascular medicine to nephrology — chosen because they matter across specialties, not just within one.
The corridor between corridors.
────────────────────────────
JULY 2026
Retatrutide takes its place in the data
Three to five things across the diabetes innovation landscape.
— GLP-1 combos and beta-cell survival
— NPWT in outpatient wound care
— A quiet shift in nephrology guidelines
Plus: From the field this month.
Read the July letter →
────────────────────────────
JUNE 2026
Innovation across silos: our first letter
Three to five things across the diabetes innovation landscape.
— GLP-1s reach type 1 diabetes
— Limb preservation as a prerequisite for cancer care
— Retatrutide, the triple agonist, takes its place in the data
— Beta-cell replacement therapies cross another threshold
Plus: What I'm watching this month.
Read the June letter →
OneGuild Pulse is a free monthly publication of OneGuild Institute. Forward freely.
Subscribe at oneguild.org/pulse. Find us on Instagram at @diabetespulse.
